Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
ATAI Life Sciences N.V. completed an acquisition involving Beckley Psytech Limited for $39,999,999.10 (closed 2024-01-03).
- Action
- acquisition
- Counterparty
- Beckley Psytech Limited
- Consideration
- $39,999,999.10
- Closing
- 2024-01-03
Exact text from the filing
On January 3, 2024 (the “Completion Date”), atai Life Sciences N.V. (the “Company”) entered into a subscription and shareholders’ agreement with Beckley Psytech Limited, a company incorporated in England and Wales (“BPL”), and certain other shareholders of BPL as identified in such agreement (the “SSA”). Pursuant to the terms of the SSA, the Company (a) acquired 24,096,385 newly issued series C preferred shares, par value £0.0001 per share, of BPL (the “Series C Shares”) for a total purchase price of $39,999,999.10 (the “Primary Investment”);
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ATAI Life Sciences N.V. entered into Subscription and Shareholders' Agreement with Beckley Psytech Limited valued at $49,999,999.50 (effective 2024-01-03).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Beckley Psytech Limited
- Value
- $49,999,999.50
- Effective
- 2024-01-03
Exact text from the filing
On January 3, 2024 (the “Completion Date”), atai Life Sciences N.V. (the “Company”) entered into a subscription and shareholders’ agreement with Beckley Psytech Limited, a company incorporated in England and Wales (“BPL”), and certain other shareholders of BPL as identified in such agreement (the “SSA”).
View on SEC.gov